Regenerative medical products derived from animal tissue have been used to successfully treat millions of patients. As they are manufactured from animal sources, there are bio-contamination and biocompatibility risks that must be addressed in accordance with ISO 22442 for receipt of the CE Mark and subsequent EU commercialisation. This article discusses important regulatory animal sourcing requirements associated with medical devices that cover these biological risks. These requirements include risk management, animal health controls, quality system elements, and demonstration of safety related to potential transmissible pathogens. The necessary information needs to be presented in the form of reports, risk analyses, and other documentation.
Editor-in-Chief
Co-Editors
Managing Editor
Victoria White
Associate Editors
Section Editors
Biotechnology
Digital Communication
EMWA News
Gained in Translation
Getting Your Foot in the Door
Good Writing Practice
In the Bookstores
Manuscript Writing
Medical Communications/Writing for Patients
Medical Devices
My First Medical Writing
News from the EMA
Out on Our Own
Pharmacovigilance
Regulatory Matters
Regulatory Public Disclosure
Teaching Medical Writing
The Crofter: Sustainable Communications
Veterinary Writing
Editors Emeritus
Lay out Designer
Chris Monk